Journal of Thyroid Disorders & Therapy
Open Access

Division of Pathology, Omori Red Cross Hospital, Tokyo, Japan

Biography

Atsuhiko Sakamoto is a Senior Managing Director in the Private Equity Group and is based in Tokyo. Before joining Blackstone, Mr. Sakamoto was a Managing Director at Bain Capital where he focused on private equity investments in Japan. Prior to joining Bain Capital, he was a Vice President and Associate at Ripplewood.

Publications

• Original Research Article   
  Factors Influencing the Chemo-Sensitivity of Weekly Paclitaxel for Anaplastic Thyroid Cancer: A Clinico-Pathologic Analysis of Cases Enrolled in a Clinical Trial
  Author(s): Naoyoshi Onoda*, Mitsuyoshi Hirokawa, Kennichi Kakudo, Atsuhiko Sakamoto, Kiminori Sugino, Noriaki Nakashima, Nobuyasu Suganuma, Shinichi Suzuki, Ken-ichi Ito and Iwao Sugitani
  
  This study was conducted to identify the clinico-pathologic factors influencing the response to weekly paclitaxel treatment for Anaplastic Thyroid Cancer (ATC), a rare refractory disease. We investigated clinico-pathological factors as well as the expressions of Ki67, p53, MAD2, TLE3, ALDH1, β-tubulin, E-cadherin and vimentin among the subjects enrolled in a recent nationwide clinical trial of 56 patients with ATC in Japan. We compared the factors of eight responders and eight non-responders. The responders survived significantly longer than the non-responders (median 11.6 vs. 3.6 months, p=0.039). No significant between-group difference was found in histological subtype, TNM classification, or the expression of Ki67, p53, MAD2, TLE3, ALDH1, β-tubulin, E-cadherin or vimentin. When the patients' Prognostic Index (PI) was determined with the sum of four clinical factors, i.. View More»
  

  Abstract PDF